Table 3.
Characteristics of patients receiving second-line cabazitaxel versus second-line androgen receptor-targeted therapy at initiation of second-line therapy
| Characteristics | Second-line therapy received | p value | |
|---|---|---|---|
| Cabazitaxel N = 123 |
AR-targeted therapy N = 506 |
||
| Age, years, mean ± SD (median) | 71.5 ± 9.2 (72.0) | 72.3 ± 9.0 (73.0) | 0.478 |
| Age, n (%) | |||
| <65 years | 27 (22.0) | 98 (19.4) | 0.520 |
| 65–74 years | 42 (34.1) | 188 (37.2) | 0.534 |
| ≥75 years | 54 (43.9) | 220 (43.5) | 0.932 |
| ECOG performance status, n (%) | |||
| 0 | 15 (12.2) | 60 (11.9) | 0.918 |
| 1 | 19 (15.4) | 83 (16.4) | 0.796 |
| 2 | 7 (5.7) | 24 (4.7) | 0.663 |
| 3 | 0 (0.0) | 15 (3.0) | – |
| Unknown | 81 (65.9) | 323 (63.8) | 0.675 |
| Number of metastases, mean ± SD (median) | 1.1 ± 0.4 (1.0) | 1.1 ± 0.4 (1.0) | 0.860 |
| Bone metastasis, n (%) | 90 (73.2) | 325 (64.2) | 0.061 |
| Visceral metastasis, n (%) | 10 (8.1) | 24 (4.7) | 0.136 |
| Lymph node metastasis, n (%) | 3 (2.4) | 35 (6.9) | 0.062 |
| Unknown, n (%) | 30 (24.4) | 160 (31.6) | 0.117 |
| PSA, ng/mL, mean ± SD (median) | 386.6 ± 760.5 (126.6) | 233.9 ± 659.4 (47.0) | 0.001* |
| ALP, u/L, mean ± SD (median) | 182.0 ± 189.7 (131.0) | 167.3 ± 240.2 (91.0) | 0.016* |
| LDH, u/L, mean ± SD (median) | 347.7 ± 291.4 (241.0) | 589.8 ± 1904.2 (221.0) | 0.122 |
| Albumin, g/dL, mean ± SD (median) | 3.9 ± 3.4 (3.7) | 3.9 ± 3.5 (3.8) | 0.522 |
| Hemoglobin, g/dL, mean ± SD (median) | 10.8 ± 1.5 (10.9) | 11.5 ± 2.0 (11.4) | <0.001* |
| Halabi risk score, mean ± SD (median)a | 153.6 ± 49.2 (154.5) | 143.8 ± 53.8 (136.4) | 0.013* |
| Low risk, n (%) | 47 (38.2) | 261 (51.6) | 0.008* |
| Intermediate risk, n (%) | 55 (44.7) | 169 (33.4) | 0.019* |
| High risk, n (%) | 21 (17.1) | 76 (15.0) | 0.572 |
| Opioid use in prior 365 days, n (%) | 53 (43.1) | 231 (45.7) | 0.609 |
| Duration of second-line therapy, months, mean ± SD (median) | 4.2 ± 1.9 (2.8) | 6.1 ± 1.9 (4.7) | 0.001* |
AR androgen receptor, ALP alkaline phosphatase, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PSA prostate-specific antigen, SD standard deviation
aBased on Halabi et al. [18]
* Denotes significant p value at the 5% level